MarketPulse
A

$ATOS

2 articles found
2 positive
0 negative
0 neutral
BenzingaBenzinga··Atossa Therapeutics Inc

Atossa Therapeutics Advances (Z)-Endoxifen Pipeline With FDA Orphan Designations

Atossa Therapeutics reported Q1 2026 expenses of $9.9M, secured FDA orphan drug designation for lead candidate (Z)-endoxifen in rare diseases.
ATOSclinical developmentbreast cancer
GlobeNewswire Inc.GlobeNewswire Inc.··Equity-Insider.Com

Patent Cliff Accelerates Biotech Rotation: Five Precision Oncology Firms Poised for Breakthrough

Institutional investors rotate capital to precision oncology biotech as patent cliff pressures Big Pharma. Five clinical-stage companies positioned for M&A amid $303B market opportunity.
SNSEONCYTNGXOSTXATOSFDA approvalbiotech